Agios Pharmaceuticals Inc. (AGIO)

Oncology Corporate Profile

Stock Performance

66.5300
0.4600

3 Month Stock History Chart

HQ Location

38 Sidney Street, 2nd Floor
Cambridge, MA 2139

Company Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and inborn errors of metabolism, or IEMs, which are a subset of orphan genetic metabolic diseases.

Website: http://www.agios.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ivosidenibIDH1 inhibitorAcute Myelogenous Leukemia (AML)III
ivosidenibIDH1 inhibitorCholangiocarcinomaIII
enasidenibIDH2m inhibitorRelapsed/refractory Acute Myelogenous Leukemia (AML)IIICelgene
enasidenibIDH2m inhibitorFrontline Acute Myelogenous Leukemia (AML)IICelgene
ivosidenibIDH1 inhibitorVarious cancer typesI
AG-881IDH1 inhibitorVarious cancer typesICelgene

View additional information on product candidates here »

Source: http://www.agios.com

Recent News Headlines

Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML

10/12/2016 04:29 pm

(NASDAQ) Oct 12, 2016 - Companion diagnostic technology to be utilized with enasidenib (AG-221/CC-90007) and AG-120 development programs for relapsed/refractory acute myeloid leukemia (AML); approximately 20% of AML patients have an IDH mutation.

Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene

9/7/2016 05:05 pm

(TheStreet) Sept 7, 2016 - The first targeted blood cancer drug from Agios Pharmaceuticals will be submitted for approval in the U.S. by the end of the year, faster than investors expected.

Agios Anemia Drug Data Hits the Mark and Raises Some Questions

6/13/2016 05:23 pm

(TheStreet) June 13, 2016 - Agios Pharmaceuticals said its experimental drug AG-348 increased hemoglobin levels in nine of 18 patients with a rare, inherited form of anemia treated in a clinical trial.

Cancer Patients Miss Appointments, Prescriptions Due To Inability To Afford Care

6/6/2016 02:02 pm

(UNC Health Care) June 3, 2016 - More than one-in-four cancer patients had to pay more for medical care than they could afford, according to a study led by UNC Lineberger member Stacie Dusetzina, PhD. A reported 18 percent were unable to afford their prescription medications.

Agios Shopped New Cancer Research Program Around Before Partnering With Celgene

5/19/2016 05:53 pm

(Boston Business Journal/BioFlash blog) May 18, 2016 - Agios Pharmaceuticals shopped around its newly-announced research program on metabolic immuno-oncology to other biotechs before deciding to go with its partner since 2010, Celgene, according to executives.

Agios, Celgene Jump into Immuno-Oncology in Revamped Alliance

5/18/2016 05:44 pm

(Xconomy Boston) May 17, 2016 - Agios Pharmaceuticals rode a wide-ranging partnership with Celgene to a big IPO a few years ago. Today the two companies are partnering once again in a deal that will see Agios try its hand at the increasingly competitive field of cancer immunotherapy.

Celgene, Agios Expand, Amend Cancer Drug Partnership

5/18/2016 04:52 pm

(TheStreet) May 17, 2016 - Celgene is paying $200 million for development rights to early research Agios is conducting into new drug targets that alter the metabolism of immune cells to help kill cancer cells.

Celgene, Agios Expand, Amend Cancer Drug Partnership

5/18/2016 11:22 am

(TheStreet) May 17, 2016 - Celgene is paying $200 million for development rights to early research Agios is conducting into new drug targets that alter the metabolism of immune cells to help kill cancer cells.

CancerCare® Releases Landmark Patient Access and Engagement Report

5/11/2016 11:03 am

(CancerCare) May 11, 2016 - A landmark report illustrating the many physical, emotional, financial, practical and informational needs cancer patients experience during and after clinical treatment was released today by CancerCare, a national nonprofit organization that provides free psychosocial support, education and financial assistance to anyone affected by cancer.

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

3/30/2016 04:58 pm

(Yahoo! Finance) Mar 30, 2016 - Agios Pharmaceuticals, Inc. today announced the initiation of a Phase 1/2, multicenter, international, open-label study, sponsored by Celgene Corporation, of AG-221 or AG-120 in combination with VIDAZA® (azacitidine for injection) in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are not eligible for intensive chemotherapy.

Bayer Joins Forces with Advocacy Organizations to Support Disease Education During Colon Cancer Awareness Month

3/1/2016 11:04 am

(Bayer) Mar 1, 2016 - To mark Colorectal Cancer Awareness Month, Bayer unites with patient advocacy organizations Colon Cancer Alliance and Fight Colorectal Cancer to raise greater awareness about the disease and its progression.

Waste in Cancer Drugs Costs $3 Billion a Year, a Study Says

3/1/2016 06:05 am

(New York Times) Mar 1, 2016 - Many drug makers exclusively sell one-size-fits-all vials, meaning patients pay thousands for medicine they are never given, researchers say.

Sparing Ovaries and Removing Fallopian Tubes May Cut Cancer Risk, But Few Have Procedure

1/21/2016 11:05 am

(Yale News) Jan 21, 2016 - During hysterectomies for non-cancerous conditions, removing both fallopian tubes while keeping the ovaries may help protect against ovarian cancer while preserving hormonal levels, but few women receive this surgical option, according to a new study by Yale School of Medicine researchers.

Agios Outlines Key 2016 Goals and Priorities

1/11/2016 05:13 pm

(TheStreet) Jan 11, 2016 - Complete enrollment of 125-patient expansion cohorts for AG-221 and AG-120 in relapsed/refractory acute myeloid leukemia in second half of 2016; present first data from phase 2 DRIVE PK study for AG-348 in PK deficiency and phase 1 healthy volunteer study for AG-519 in first half of 2016; initiate preclinical development of a program from the next wave of research.

To Discover Better Drugs Faster, MD Anderson Is Innovating How It Innovates

1/5/2016 12:04 pm

(Forbes) Jan 4, 2016 - At MD Anderson they’re working on a new, more integrated model they hope will revolutionize the pharmaceutical industry and early signs suggest that it’s working.

Merck’s Erbitux Approved For NHS Wales

1/5/2016 12:04 pm

(Pharmafile [UK]) Jan 5, 2016 - The All Wales Medicines Strategy Group has recommended Merck’s Erbitux in combination with chemotherapy for restricted use in the NHS in Wales.

Opinion: Oncology’s Future: Liquid Biopsies and the Heterogeneity of Cancer

1/5/2016 12:04 pm

(Xconomy San Diego) Jan 5, 2016 - The root of the problem is not oncologists, but rather the diagnostics tools available to them.

Dr. Paul Janssen Award for Biomedical Research Issues 2016 Call for Nominations

1/5/2016 12:04 pm

(bizjournals.com) Jan 5, 2016 - The Dr. Paul Janssen Award for Biomedical Research today opens its 2016 call for nominations. This prestigious award recognizes individuals whose basic or clinical discoveries have made, or have the potential to make, significant contributions toward improving human health.

Nanobiotix Starts A New Research Program, In Immuno Oncology, With Its Lead Product NBTXR3

1/5/2016 12:03 pm

(Nanobiotix) Jan 5, 2016 - Nanobiotix, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology.

Risk of Heart Damage Follows Some Childhood Cancer Survivors

1/5/2016 12:02 pm

(Reuters Health) Jan 4, 2016 - Childhood cancer survivors may face an increased risk of heart damage after exposure to certain chemotherapy and radiation treatments, a U.S. analysis suggests.

Novel RNA Delivery System May Treat Incurable Blood Cancers

1/5/2016 12:02 pm

(TAU) Jan 5, 2016 - TAU researchers develop unique system to deliver therapy at site of Mantle Cell Lymphoma.

Oncodesign Biotechnology and Bristol-Myers Squibb Enter into Strategic Drug Discovery Collaboration

1/5/2016 12:02 pm

(Yahoo! Finance) Jan 5, 2016 - Oncodesign today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds.

Circulating Tumor Cells Linked With Treatment Resistance And Response In Prostate Cancer Patients

1/5/2016 12:01 pm

(Epic Sciences) Jan 4, 2016 - Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies.

Twin Study Estimates Familial Risks Of 23 Different Cancers

1/5/2016 12:01 pm

(Harvard T.H. Chan School of Public Health) Jan 5, 2016 - A large new study of twins has found that having a twin sibling diagnosed with cancer poses an excess risk for the other twin to develop any form of cancer.

Triple Lung Cancer Therapy With Experimental Drugs And Radiation Targets Most Resistant Cancers

1/5/2016 12:01 pm

(Thomas Jefferson/Sidney Kimmel Cancer Center blog) Jan 4, 2016 - One new study out of Thomas Jefferson University in Philadelphia has been experimenting with a triple therapy that has proved effective for KRAS gene mutations in mice. The triple therapy involves two experimental drugs in combination with radiation therapy.

Improving Access To Clinical Trials When Biopsies Are Required

1/5/2016 12:01 pm

(IASLC) Jan 4, 2016 - The requirement for tumor tissue specimens and associated analyses in order to participate in clinical trials appears to be a significant barrier to clinical trial enrollment and may delay treatment.

New Paste Prevents Scarring Caused by Radiation Therapy for Cancer

1/5/2016 12:01 pm

(NYU Langone) Jan 4, 2016 - An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy.

Which Kidney Cancer Drug on Progression? Surprising Answers

1/5/2016 11:05 am

(Medscape Medical News) Jan 5, 2016 - Phase 3 data presented on the oral agent cabozantinib (Cometriq, Exelixis) during a presscast held in advance of the Genitourinary Cancers Symposium 2016 reaffirm that it provides an unprecedented benefit in slowing the progression of advanced kidney cancer in the second-line setting.

Regular Use of Aspirin May Lower Men’s Risk of Advanced Prostate Cancer

1/5/2016 11:04 am

(Wall Street Journal) Jan 4, 2016 - Researchers reported that men who took at least three aspirins a week reduced their risk of developing or dying from advanced prostate cancer.

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

12/18/2015 05:34 pm

(Yahoo! Finance) Dec 18, 2015 - Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1b, multicenter, international, open-label study of AG-221 or AG-120 in combination with induction and consolidation therapy in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are eligible for intensive chemotherapy.

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

12/7/2015 09:21 pm

(Agios) Dec 6, 2015 - Patients on study for up to 18 months with a median response duration of 6.9 months in relapsed/refractory acute myeloid leukemia (AML); enrollment complete for four 25-patient expansion cohorts; 125-patient expansion cohort and phase 3 IDHENTIFY study open for enrollment.

Agios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

12/6/2015 08:43 pm

(TheStreet) Dec 5, 2015 - Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced new data from the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced hematologic malignancies.

Agios Extends Reach of Cancer Metabolism Drug into Solid Tumors

11/9/2015 04:41 pm

(TheStreet) Nov 8, 2015 - The first presentation of solid tumor results Sunday from Agios Pharmaceuticals' cancer metabolism drug AG-120 met expectations -- a lot of arrested tumor growth in patients with advanced cancers that are difficult to treat.

Agios Outlines Key Clinical Development & Research Strategies

10/16/2015 04:10 pm

(Agios) Oct 16, 2015 - Agios Pharmaceuticals announced its clinical development strategy for the company's lead cancer metabolism and rare genetic metabolic disorders programs, along with insights into emerging research at its R&D Day today.

ASCO’s Quality Training Program Leads to Improvement Learning in Oncology

8/19/2015 11:04 am

(ASCO in Action) Aug 18, 2015 - A new article published in the Journal of Oncology Practice studies how structured training programs improve health professionals’ skills in performing clinical care and research.

GE Healthcare First to Receive FDA Clearance for Low Dose CT Lung Cancer Screening

8/17/2015 11:03 am

(GE Healthcare) Aug 17, 2015 - GE Healthcare is proud to be the first company with a low dose computed tomography (CT) lung cancer screening option that is cleared by the U.S. FDA for lung cancer screening.

Advance in Photodynamic Therapy Offers New Approach to Ovarian Cancer

8/14/2015 10:05 am

(OSU) Aug 13, 2015 - Researchers at Oregon State University have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors.

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

6/24/2015 04:41 pm

(TheStreet) June 24, 2015 - Third IDH mutant inhibitor to enter clinical trials; brain penetration and pan-IDHM inhibition broaden development options for IDH mutant-positive cancers, including gliomas; second phase 1 study in hematologic malignancies on track to begin dosing in coming weeks.

Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

6/12/2015 04:23 pm

(Agios) June 12, 2015 - Agios Pharmaceuticals, Inc. presented today new, final data from its Phase 1 multiple ascending dose (MAD) clinical trial of AG-348 in healthy volunteers in an oral presentation at the 20th Congress of the European Hematology Association (EHA) taking place June 11-14, 2015 in Vienna.

Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

6/12/2015 04:22 pm

(Agios) June 12, 2015 - Agios Pharmaceuticals, Inc. today announced new data from the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced hematologic malignancies presented at the 20th Congress of the European Hematology Association (EHA) taking place June 11-14, 2015 in Vienna.

Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

6/12/2015 04:21 pm

(Agios) June 12, 2015 - Agios Pharmaceuticals, Inc. today announced new data from the dose-escalation phase and expansion cohorts from the ongoing Phase 1 study evaluating single agent AG-221, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-2 (IDH2), in advanced hematologic malignancies.

Agios 'Cancer Metabolism' Drugs Induce Prolonged Responses in Blood Cancer Patients

6/12/2015 03:55 pm

(TheStreet) June 12, 2015 - Two experimental drugs from Agios Pharmaceuticals designed to curb the overactive metabolism of certain kinds of mutated blood cancer cells are showing prolonged responses not normally seen in patients with advanced disease, according to new study results announced Friday.

Agios Leukemia Drug Demonstrates Impressive Response Rate: Study

6/12/2015 11:59 am

(Reuters) June 12, 2015 - Forty percent of patients, most with a particularly aggressive form of leukemia, responded to an experimental Agios Pharmaceuticals Inc drug, including several who experienced complete remission, according to data presented at a medical meeting on Friday.

Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

6/11/2015 04:53 pm

(MarketWatch) June 10, 2015 - Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-120 for treatment of patients with acute myelogenous leukemia (AML).

Pancreatic Cancer Action Network's Enhanced Patient Services and Clinical Initiatives to Transform the Fight Against Pancreatic Cancer

6/9/2015 12:02 pm

(NEWS.GNOM.ES) June 9, 2015 - The Clinical Trial Finder is the latest initiative that the Pancreatic Cancer Action Network is bringing to market for the pancreatic cancer community as part of its increased efforts to double survival of pancreatic cancer.

Agios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation

5/18/2015 04:58 pm

(StreetInsider) May 18, 2015 - Agios Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-120 for the treatment of patients with acute myelogenous leukemia (AML) who harbor an isocitrate dehydrogenase-1 (IDH1) mutation.

Agios Pharmaceuticals Selects Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development

4/29/2015 04:45 pm

(NASDAQ) Apr 29, 2015 - Agios Pharmaceuticals, Inc. today announced that it plans to advance into clinical development AG-881, a small molecule that has shown in preclinical studies to fully penetrate the blood brain barrier and inhibit isocitrate dehydrogenase-1 (IDH1) and IDH2 mutant cancer models, in collaboration with its cancer metabolism partner Celgene Corporation.

Stada Agrees Oncology Deal With Indian Hetero Drugs

3/26/2015 12:03 pm

(Reuters) Mar 26, 2015 - German generic drugmaker Stada struck an alliance with family-owned Hetero Drugs Ltd of India to gain access to active ingredients for cancer drugs, Stada said on Thursday.